Refine
Year of publication
Document Type
- Preprint (693)
- Article (591)
- Working Paper (10)
- Conference Proceeding (3)
- Part of Periodical (2)
- Part of a Book (1)
- Report (1)
Has Fulltext
- yes (1301)
Is part of the Bibliography
- no (1301)
Keywords
- Heavy Ion Experiments (20)
- Hadron-Hadron Scattering (11)
- Hadron-Hadron scattering (experiments) (11)
- LHC (9)
- Heavy-ion collision (6)
- ALICE experiment (4)
- Collective Flow (4)
- Hepatocellular carcinoma (4)
- Jets (4)
- Quark-Gluon Plasma (4)
- ALICE (3)
- COVID-19 (3)
- Cirrhosis (3)
- Gene expression (3)
- HIV (3)
- Heavy Ions (3)
- Immunology (3)
- Inflammation (3)
- Jets and Jet Substructure (3)
- Liver diseases (3)
- cancer (3)
- child (3)
- pp collisions (3)
- Antitrust (2)
- Beauty production (2)
- Bone density (2)
- Charm physics (2)
- Consumer Welfare (2)
- Diagnostic markers (2)
- Ewing sarcoma (2)
- Experimental nuclear physics (2)
- Experimental particle physics (2)
- HCC (2)
- Heavy Quark Production (2)
- Lepton-Nucleon Scattering (experiments) (2)
- Literaturtheorie (2)
- MLL (2)
- Mouse models (2)
- Oncology (2)
- Osteoporosis (2)
- Particle Correlations and Fluctuations (2)
- Particle and resonance production (2)
- Particle correlations and fluctuations (2)
- Pb–Pb collisions (2)
- Psychiatric disorders (2)
- QCD (2)
- Relativistic heavy-ion collisions (2)
- SARS-CoV-2 (2)
- Single electrons (2)
- Sustainability (2)
- aortic stenosis (2)
- biomarker (2)
- children (2)
- cirrhosis (2)
- habitat destruction (2)
- hematopoietic stem cell transplantation (2)
- hepatitis C virus (2)
- invasive fungal disease (2)
- lung cancer (2)
- proteomics (2)
- soft tissue sarcoma (2)
- sphingolipids (2)
- web archiving (2)
- 15-PGDH (1)
- 8 weeks (1)
- 900 GeV (1)
- ACURATE neo (1)
- AKI (1)
- ALICE detector (1)
- ALK-rearranged NSCLC (1)
- ALL (1)
- AML (1)
- APRI (1)
- Accelerators & Beams (1)
- Accelerators & storage rings (1)
- Actin (1)
- Active middle ear implants (1)
- Acute coronary syndrome (1)
- Acute myeloid leukemia (1)
- Adenylyl cyclase (1)
- Amino acid analysis (1)
- Anandamide (1)
- Angiogenesis (1)
- Animal models (1)
- Anti-nuclei (1)
- Antibiotic steward-ship (1)
- Antibiotic therapy (1)
- Antibiotics (1)
- Antiretroviral therapy (1)
- Antiretrovirals (1)
- Antiviral therapy (1)
- Apoptosis (1)
- Artificial Intelligence (1)
- Ataxia-telangiectasia (1)
- Atomic & molecular beams (1)
- Atomic, Molecular & Optical (1)
- Atoms (1)
- Atrial fibrillation (1)
- Auditory system (1)
- Autologous stem cell transplantation (1)
- Autorschaft (1)
- BFIS (1)
- BRAF (1)
- Backscattering (1)
- Beam loss (1)
- Biodiversity Data (1)
- Biomarker (1)
- Biomarkers (1)
- Biomass monitoring (1)
- Biomonitoring (1)
- Bioprocess automation (1)
- Bipolar disorder (1)
- Blood plasma (1)
- Bone conduction devices (1)
- Bone diseases, Metabolic (1)
- Boosted Jets (1)
- Botanical Collections (1)
- Breast cancer (1)
- Breast tumors (1)
- Buprestidae (1)
- C6 ceramide (1)
- CCL2 (1)
- CEP68 (1)
- COMT (1)
- COVID 19 (1)
- CRISPR/Cas (1)
- CT (1)
- CT dual-energy computed tomography (1)
- CVID (1)
- Cancer (1)
- Cancer chemotherapy (1)
- Cancer detection and diagnosis (1)
- Cancer treatment (1)
- Canopy height model (1)
- Cardiac hypertrophy (1)
- Cardiac surgery (1)
- Cardiac troponin (1)
- Cardiology (1)
- Cardiovascular biology (1)
- Cardiovascular disease risk (1)
- Cardiovascular diseases (1)
- Cell binding (1)
- Cell membranes (1)
- Cell staining (1)
- Centrality Class (1)
- Centrality Selection (1)
- Cerambycidae (1)
- Charge fluctuations (1)
- Charge-transfer collisions (1)
- Checkpoint inhibitor (1)
- Chronic hepatitis C (1)
- Circular accelerators (1)
- Cleanliness level (1)
- Clinical Trials and Observations (1)
- Clinical genetics (1)
- Collective Flow, (1)
- Colon capsule endoscopy (1)
- Colorectal cancer (1)
- Comparison with QCD (1)
- Complementation rate (1)
- Computer-aided drug design (1)
- Congenital anomalies (1)
- Consensus statement (1)
- Conservation (1)
- CuveWaters (1)
- C‐reactive protein (1)
- DNA sequence analysis (1)
- DST (1)
- Data sharing (1)
- Denervation (1)
- Diauxic effects (1)
- Differentiation (1)
- Digestive system procedures (1)
- Digitization (1)
- Dilated cardiomyopathy (1)
- Direct Acting Antivirals (DAA) (1)
- Drug susceptibility testing (1)
- Dual-energy computed tomography (1)
- ESBL (1)
- ESG (1)
- ETP-ALL (1)
- Early goal-directed therapy (1)
- Eicosanoids (1)
- Electroantennography (1)
- Electron-pion identification (1)
- Electronic transitions (1)
- Electroweak interaction (1)
- Elliptic flow (1)
- Embryos (1)
- Empirische Ästhetik (1)
- European Society for Immunodeficiencies (ESID) (1)
- Extended donor criteria (1)
- F508del homozygous (1)
- FDM (1)
- FGFR (1)
- FIB-4 (1)
- FLT3 (1)
- Fatty acids (1)
- Fatty liver (1)
- Femtoscopy (1)
- Fibre/foam sandwich radiator (1)
- Fibrosis (1)
- Fibrotest (1)
- Filovirus cell entry; attachment factors redundancy; SH-SY5Y cell line; host–pathogen interactions (1)
- Flow cytometry (1)
- Forschung (1)
- Forschungsdatenmanagement (1)
- Functional clustering (1)
- G-protein-coupled receptors (1)
- GWAS (1)
- Gastric cancer (1)
- Genetic causes of cancer (1)
- Genetic testing (1)
- Genetics (1)
- Genome editing (1)
- German PID-NET registry (1)
- Gomphus flavipes (1)
- Guanine nucleotide exchange factors (1)
- Guanosine triphosphatase (1)
- Gαq/11 (1)
- HBT (1)
- HBV (1)
- HCV (1)
- HDAC4 (1)
- HIF1α (1)
- HIPPO signalling (1)
- HIV-1 (1)
- HNO (1)
- Hadron production (1)
- Hadron-Hadron Scattering Heavy (1)
- Hadron-hadron interactions (1)
- Hals-Nasen-Ohren-Heilkunde (1)
- Haploidentical stem cell transplantation (1)
- Hard Scattering (1)
- Health policy (1)
- Heart (1)
- Heavy Ion Experiment (1)
- Heavy flavor production (1)
- Heavy flavour production (1)
- Heavy ions (1)
- Heavy-flavour decay muons (1)
- Heavy-flavour production (1)
- Heavy-ion collisions (1)
- Hepatitis B virus (1)
- Hepatitis C (1)
- Hepatitis C virus (1)
- Hepatotoxicity (1)
- Herbaria (1)
- High-dose chemotherapy (1)
- Histology (1)
- Homeostasis (1)
- Hsp70 (1)
- Human genetics (1)
- Hypertension (1)
- Hypoxic responses (1)
- IHC (1)
- IWRM (1)
- Icelandic Family Sagas (1)
- IgG substitution therapy (1)
- Immunogenetics (1)
- Inclusive spectra (1)
- Incomplete colonoscopy (1)
- Infection (1)
- Intensity interferometry (1)
- Intensive care unit (1)
- International Law (1)
- Internationales Recht (1)
- Interventional oncological treatment (1)
- Intravenous injections (1)
- Invariant Mass Distribution (1)
- Ionisation energy loss (1)
- Ions (1)
- Jet Physics (1)
- Jet Substructure (1)
- KDIGO (1)
- KIR (1)
- Konstitutionalismus (1)
- Kupffer cells (1)
- LCH (1)
- Landesinitiative (1)
- Landesinitiative für Forschungsdatenmanagement (1)
- Langerhans cell histiocytosis (1)
- Laser interstitial thermal therapy (1)
- Lehre (1)
- Lenalidomide (1)
- Libellen (1)
- Library screening (1)
- Literarischer Stil (1)
- Literaturwissenschaft (1)
- Liver (1)
- Liver cancer (1)
- Liver cirrhosis (1)
- Liver enzymes (1)
- Liver fibrosis (1)
- Liver transplantation (1)
- Long non-coding RNAs (1)
- Low & intermediate-energy accelerators (1)
- Low volume prep (1)
- Luciferase (1)
- Lymphoid Neoplasia (1)
- Lyrik (1)
- M. Intracellulare (1)
- M. avium (1)
- M. avium complex (1)
- M. chimaera (1)
- MALAT1 (1)
- MRP4 (1)
- Macrophages (1)
- Marker genes (1)
- Material budget (1)
- Mechanisms of disease (1)
- Mena/VASP (1)
- Mesenchymal stem cells (1)
- Metabolic shift (1)
- Metabolism (1)
- Microbiology and Infectious Disease (1)
- Microglial cells (1)
- Microwave ablation (1)
- Mid-rapidity (1)
- Minimal residual disease (1)
- Minimum Bias (1)
- Mixed hearing loss (1)
- Mongolia (1)
- Monochamus galloprovincialis (1)
- Monte Carlo (1)
- Mortality (1)
- Moviprep (1)
- Multi-Parton Interactions (1)
- Multi-nucleated cardiomyocytes (1)
- Multi-stakeholder approach (1)
- Multi-strange baryons (1)
- Multi-wire proportional drift chamber (1)
- Multidrug-resistant organisms (1)
- Multiple myeloma (1)
- Multivariate analysis (1)
- Muscle atrophy (1)
- Musikästhetik (1)
- Mutation databases (1)
- Myocardial infarction (1)
- NCoR1 (1)
- NFDI (1)
- NK cells (1)
- NMR spectroscopy (1)
- NOTCH1 (1)
- NTM (1)
- Nachhaltigkeit (1)
- Namibia (1)
- Nationale Forschungsdateninfrastruktur (1)
- Neural network (1)
- Neurons (1)
- Neuroästhetik (1)
- Non-tuberculous mycobacteria (1)
- Nuclear astrophysics (1)
- Nuclear modification factor (1)
- Nuclear physics of explosive environments (1)
- Nuclear reactions (1)
- Nucleus accumbens (1)
- ORL (1)
- Oncogenes (1)
- Online monitoring (1)
- Ophiogomphus cecilia (1)
- Optogenetics (1)
- Organ allocation (1)
- Orphan disease (1)
- Osteoporotic fractures (1)
- Otorhinolaryngology (1)
- Ovarian cancer (1)
- PD-L1 (1)
- PGE2 (1)
- PID prevalence (1)
- PKA (1)
- PKD (1)
- PKD/IC (1)
- PRRT2 (1)
- PYTHIA (1)
- Pancreas transplantation (1)
- Parallelisation (1)
- Particle and Resonance Production (1)
- Pb–Pb (1)
- Periodontal disease (1)
- Periodontal therapy (1)
- Perturbative methods (1)
- Phaenops cyanea (1)
- Phantoms (imaging) (1)
- Phospho-soda (1)
- Phosphorylation (1)
- Photon counting (1)
- PillCamColon2 (1)
- Plasminogen (1)
- Platelets (1)
- Polyps (1)
- Portal veins (1)
- Production Cross Section (1)
- Properties of Hadrons (1)
- Prostaglandin (1)
- Proton–proton (1)
- Pulsed SILAC (1)
- QGP (1)
- Quark Deconfinement (1)
- Quark Gluon Plasma (1)
- Quark Production (1)
- Quark gluon plasma (1)
- Quarkonium (1)
- RDM (1)
- RNA (1)
- RNA, long noncoding (1)
- RNA-binding proteins (1)
- Radiative capture (1)
- Random forest (1)
- Rapidity Range (1)
- Regression analysis (1)
- Rehabilitation (1)
- Rejection (1)
- Relapse (1)
- Relativistic heavy ion physics (1)
- Renal cell carcinoma (1)
- Research (1)
- Research Article (1)
- Research Data Management (1)
- Research Infrastructure (1)
- Residency (1)
- Resolution Parameter (1)
- Riftia pachyptila (1)
- S. cerevisiae (1)
- SARS CoV 2 (1)
- SARS-CoV‑2 pandemic (1)
- SARS-CoV‑2-Pandemie (1)
- SCCHN (1)
- SENP (1)
- SKI II (1)
- STED superresolution (1)
- SUMO (1)
- SVR (1)
- Safety (1)
- Sarcopenia (1)
- Scattering of atoms, molecules, clusters & ions (1)
- Scattering theory (1)
- Second-line treatment (1)
- Semantics (1)
- Sepsis-bundle (1)
- Sequence (1)
- Shake flask (1)
- Single muons (1)
- Single-cell RNA-sequencing (1)
- Small molecules (1)
- Specialist training (1)
- Spectrin (1)
- Sphingolipids (1)
- Stem cells (1)
- Surgery (1)
- Surgical and invasive medical procedures (1)
- Surgical oncology (1)
- Survival (1)
- Sustained virological response (SVR) (1)
- Systematic Uncertainty (1)
- Systemic treatment (1)
- T-ALL (1)
- TACE (1)
- TAVR (1)
- TGF-beta (1)
- TOR signalling (1)
- TP53 mutation status (1)
- TR (1)
- Targeted therapy (1)
- Taxonomy (1)
- Teaching (1)
- Technical data (1)
- Thrombosis (1)
- Thromboxane (1)
- Time Projection Chamber (1)
- Tomography (x-ray computed) (1)
- Tracking (1)
- Transarterial chemoembolization (1)
- Transcriptome analysis (1)
- Transferases (1)
- Transient elastography (1)
- Transition radiation detector (1)
- Transverse momentum (1)
- Trigger (1)
- Trousseau’s syndrome (1)
- Type 2 diabetes (1)
- Tyrosine kinase inhibitor mTOR inhibition (1)
- UAV (1)
- Ubiquitination (1)
- University hospitals (1)
- Universitätskliniken (1)
- VRE (1)
- Vector Boson Production (1)
- Veins (1)
- Vesicles (1)
- Viral load (1)
- Weiterbildung (1)
- Wettbewerbsrecht (1)
- X-ray crystallography (1)
- Xenon-based gas mixture (1)
- Yellow fluorescent protein (1)
- a-induced reactions (1)
- accessory proteins (1)
- acoustic radiation force impulse imaging (1)
- activation (1)
- acute coronary syndrome (1)
- acute leukemia (1)
- acute lymphoblastic leukemia (1)
- adenocarcinoma (1)
- adenosine receptors (1)
- aesthetic reward (1)
- age (1)
- agriculture (1)
- alcoholic hepatitis (1)
- allogeneic stem cell transplantation (1)
- amino acids (1)
- angiopoietin-like 3 (ANGPTL3) (1)
- anti-EGFR therapy (1)
- antibiotic therapy (1)
- antibodies (1)
- antiepileptic drugs (1)
- antifungal combination therapy (1)
- antifungal therapy (1)
- antimicrobial stewardship (1)
- antiviral therapy (1)
- arachidonate 12/15-lipoxygenase (Alox12/15) (1)
- architecture (1)
- ascites (1)
- atherosclerosis (1)
- atrial fibrillation (1)
- atrophy (1)
- autophagy (1)
- b-cell lymphomas (1)
- bacteremia (1)
- bendamustine (1)
- blood (1)
- bone marrow metastasis (1)
- bone metastasis (1)
- cAMP (1)
- cART (1)
- cancer surveillance (1)
- carbapenem resistance (1)
- cardiac I/R injury (1)
- cardiac remodeling (1)
- cell differentiation (1)
- cell heterogeneity (1)
- cell-free protein synthesis (1)
- centrosome (1)
- centrosome linker (1)
- ceramides (1)
- chemoembolization (1)
- chemorefractory metastatic colorectal cancer (1)
- chemotherapy regimen (1)
- children and adolescents (1)
- chills (1)
- chimeric antigen receptor t-cell therapy (1)
- chimeric antigen receptors (1)
- cholestasis (1)
- chromosomal translocations (1)
- chronic kidney disease (1)
- chronic viral hepatitis (1)
- co-infection (1)
- cohort study (1)
- computed tomography (1)
- confidence interval (1)
- confirmatory factor analysis (1)
- constitutionalisation (1)
- constitutionalism (1)
- coronary disease (1)
- critical care unit (1)
- critical ill patients (1)
- cutaneous T cell lymphoma (1)
- cystic fibrosis (1)
- dE/dx (1)
- damage detection (1)
- decision aids (1)
- demand-responsive approach (1)
- desmoplastic small round cell tumor (1)
- detector (1)
- dihydroceramide (1)
- dihydroceramides (1)
- direct-acting antivirals (1)
- disease progression (1)
- drone (1)
- eNPP2 (1)
- enrichment (1)
- entity and event extraction (1)
- epigenomics (1)
- experimental results (1)
- extraskeletal (1)
- familial infantile epilepsy (1)
- fatigue testing (1)
- fibrocytes (1)
- fibrosis (1)
- fibrotest (1)
- fine spatial resolution remote sensing (1)
- first-time shoulder dislocation (1)
- fixed-links modeling (1)
- fluid intelligence (1)
- fumonisin B1 (1)
- gap junction protein alpha 4-genotype (1)
- genetic generalized epilepsy (1)
- germ cell tumors (1)
- glass fiber reinforced materials (1)
- glecaprevir (1)
- glioblastoma (1)
- global change (1)
- graft rejection (1)
- head-and-neck cancer (1)
- heart failure (1)
- heavy ion experiments (1)
- hematopoietic cell transplantation (1)
- hemiplegic migraine (1)
- hepatic fibrosis (1)
- hepatic tumor (1)
- hepatitis C (1)
- hepatitis c (1)
- herbarium (1)
- high-dose chemotherapy (1)
- histology (1)
- homoarginine (1)
- host-microbe interaction (1)
- human knockout model (1)
- hypertension, pulmonary (1)
- idiopathic pulmonary fibrosis (1)
- immobilization in external rotation and abduction (1)
- immune checkpoint inhibitor (ICI) (1)
- immunohistochemistry (1)
- immunoprecipitation (1)
- immunotherapy (1)
- infection (1)
- infection control (1)
- infections (1)
- inflammatory markers (1)
- insulin resistance (1)
- interferon regulatory factor 9 (IRF9) (1)
- international legal theory (1)
- intraperitoneal therapy (1)
- intrinsically disordered region (1)
- ischemic type biliary lesions (1)
- knockout mouse (1)
- lamotrigine (1)
- land use (1)
- leukapheresis (1)
- leukemia (1)
- levetiracetam (1)
- lipoxin A4 (1)
- liver (1)
- liver abscess (1)
- liver cirrhosis (1)
- liver transplantation (1)
- long non-coding RNA (1)
- lung disease phenotype (1)
- lung function (1)
- lymphoma (1)
- l‐arginine:glycine amidinotransferase (1)
- maintenance therapy (1)
- malignancy (1)
- mass spectrometry (1)
- metastasis (1)
- methyltransferases (1)
- molecular characteristics (1)
- multi-resources mix (1)
- multidrug resistance (1)
- naturalization (1)
- neovascularization, physiologic (1)
- neuroaesthetics (1)
- neutralizing antibodies (1)
- neutropenia (1)
- nomadic lifestyles (1)
- non-ST-segment elevation acute coronary syndrome (1)
- non-invasive fibrosis assessment (1)
- non-neutropenic episode (1)
- nonstructural proteins (1)
- odds ratio (1)
- oral narratives (1)
- orthopic liver transplantation (1)
- outcome (1)
- ovary (1)
- p97 (1)
- parliament libraries (1)
- pediatric solid tumors (1)
- performativity (1)
- peritoneal carcinomatosis (1)
- pharmacoresistance (1)
- phenotype/genotype relation (1)
- phenotypic spectrum (1)
- pibrentasvir (1)
- piloerection (1)
- plant diversity (1)
- plant height (1)
- pneumonia (1)
- poetic language (1)
- point shear wave elastography (1)
- precision medicine (1)
- pressurized intraperitoneal aerosol chemotherapy (PIPAC) (1)
- primary biliary cirrhosis (1)
- primary immunodeficiency (1)
- primary immunodeficiency (PID) (1)
- primary sclerosing cholangitis (1)
- prognostic biomarker (1)
- quark gluon plasma (1)
- radar-based structural health monitoring (1)
- radio sensitivity (1)
- rain- and floodwater harvesting (1)
- rangeland ecosystems (1)
- rats (1)
- re-exposure (1)
- rechallenge (1)
- registry for primary immunodeficiency (1)
- reintroduction (1)
- resolution of inflammation (1)
- retrospective trial (1)
- risk assessment (1)
- rituximab (1)
- rootletin (1)
- rural-urban migration (1)
- sanitation (1)
- sarcoma (1)
- screening routine (1)
- semantic content analysis (1)
- sepsis (1)
- sequential ALK-inhibitor therapy (1)
- sex (1)
- short-chain ceramide (1)
- shortening of treatment (1)
- shoulder instability (1)
- shoulder stabilization (1)
- skeletal muscle (1)
- skin (1)
- social Web (1)
- solid tumor (1)
- sorafenib (1)
- specialized pro-resolving lipid mediators (SPMs) (1)
- spectra (1)
- sphinganine 1-phosphate (1)
- sphingolipid (1)
- sphingosine 1-phosphate (1)
- sphingosine kinase (1)
- sphingosine-1-phosphate (1)
- spike protein (1)
- steppe ecosystem (1)
- stopping rule (1)
- structural proteins (1)
- structure-from-motion photogrammetry (1)
- sulfur-oxidizing symbiont (1)
- symbiosis (1)
- tense switches (1)
- testis (1)
- text analysis (1)
- tomography (1)
- topic detection (1)
- transcatheter aortic valve replacement (1)
- transdisciplinarity (1)
- transfemoral (1)
- transient elastography (1)
- translocation partner genes (1)
- transmission (1)
- treatment (1)
- tumor microenvironment (TME) (1)
- type I interferons (IFNs) (1)
- tyrosine kinase inhibitor (TKI) (1)
- upper gastrointestinal cancer (1)
- valproic acid (1)
- variants of concern (1)
- vascular calcification (1)
- vemurafenib (1)
- versican (VCAN) (1)
- web crawler (1)
- whole-genome sequencing (1)
- wildlife mobility (1)
- wind turbine blades (1)
- working memory capacity (1)
- x-ray techniques (1)
- Ästhetik (1)
- γ-spectroscopy (1)
- гепатит С (1)
- правила прекращения лечения (1)
- противовирусные препараты прямого действия (ПППД) (1)
- сокращение лечения (1)
- устойчивый вирусологический ответ (УВО) (1)
- √sN N = 2.76 TeV (1)
Institute
- Physik (1086)
- Frankfurt Institute for Advanced Studies (FIAS) (961)
- Informatik (924)
- Medizin (160)
- Biowissenschaften (7)
- ELEMENTS (7)
- Biochemie, Chemie und Pharmazie (6)
- Sustainable Architecture for Finance in Europe (SAFE) (6)
- Wirtschaftswissenschaften (6)
- Geowissenschaften (5)
Background/Aims: Signaling of Gs protein-coupled receptors (GsPCRs) is accomplished by stimulation of adenylyl cyclase, causing an increase of the intracellular cAMP concentration, activation of the intracellular cAMP effectors protein kinase A (PKA) and Epac, and an efflux of cAMP, the function of which is still unclear.
Methods: Activation of adenylyl cyclase by GsPCR agonists or cholera toxin was monitored by measurement of the intracellular cAMP concentration by ELISA, anti-phospho-PKA substrate motif phosphorylation by immunoblotting, and an Epac-FRET assay in the presence and absence of adenosine receptor antagonists or ecto-nucleotide phosphodiesterase/pyrophosphatase2 (eNPP2) inhibitors. The production of AMP from cAMP by recombinant eNPP2 was measured by HPLC. Extracellular adenosine was determined by LC-MS/MS, extracellular ATP by luciferase and LC-MS/MS. The expression of eNPP isoenzymes 1-3 was examined by RT-PCR. The expression of multidrug resistance protein 4 was suppressed by siRNA.
Results: Here we show that the activation of GsPCRs and the GsPCRs-independent activation of Gs proteins and adenylyl cyclase by cholera toxin induce stimulation of cell surface adenosine receptors (A2A or A2B adenosine receptors). In PC12 cells stimulation of adenylyl cyclase by GsPCR or cholera toxin caused activation of A2A adenosine receptors by an autocrine signaling pathway involving cAMP efflux through multidrug resistance protein 4 and hydrolysis of released cAMP to AMP by eNPP2. In contrast, in PC3 cells cholera toxin- and GsPCR-induced stimulation of adenylyl cyclase resulted in the activation of A2B adenosine receptors.
Conclusion: Our findings show that stimulation of adenylyl cyclase causes a remarkable activation of cell surface adenosine receptors.
HLA-DRB1 and HLA-DQB1 genetic diversity modulates response to lithium in bipolar affective disorders
(2021)
Bipolar affective disorder (BD) is a severe psychiatric illness, for which lithium (Li) is the gold standard for acute and maintenance therapies. The therapeutic response to Li in BD is heterogeneous and reliable biomarkers allowing patients stratification are still needed. A GWAS performed by the International Consortium on Lithium Genetics (ConLiGen) has recently identified genetic markers associated with treatment responses to Li in the human leukocyte antigens (HLA) region. To better understand the molecular mechanisms underlying this association, we have genetically imputed the classical alleles of the HLA region in the European patients of the ConLiGen cohort. We found our best signal for amino-acid variants belonging to the HLA-DRB1*11:01 classical allele, associated with a better response to Li (p < 1 × 10−3; FDR < 0.09 in the recessive model). Alanine or Leucine at position 74 of the HLA-DRB1 heavy chain was associated with a good response while Arginine or Glutamic acid with a poor response. As these variants have been implicated in common inflammatory/autoimmune processes, our findings strongly suggest that HLA-mediated low inflammatory background may contribute to the efficient response to Li in BD patients, while an inflammatory status overriding Li anti-inflammatory properties would favor a weak response.
The antibody-drug conjugate polatuzumab vedotin (pola) has recently been approved in combination with bendamustine and rituximab (pola-BR) for patients with refractory or relapsed (r/r) large B-cell lymphoma (LBCL). To investigate the efficacy of pola-BR in a real-world setting, we retrospectively analyzed 105 patients with LBCL who were treated in 26 German centers under the national compassionate use program. Fifty-four patients received pola as a salvage treatment and 51 patients were treated with pola with the intention to bridge to chimeric antigen receptor (CAR) T-cell therapy (n = 41) or allogeneic hematopoietic cell transplantation (n = 10). Notably, patients in the salvage and bridging cohort had received a median of 3 prior treatment lines. In the salvage cohort, the best overall response rate was 48.1%. The 6-month progression-free survival and overall survival (OS) was 27.7% and 49.6%, respectively. In the bridging cohort, 51.2% of patients could be successfully bridged with pola to the intended CAR T-cell therapy. The combination of pola bridging and successful CAR T-cell therapy resulted in a 6-month OS of 77.9% calculated from pola initiation. Pola vedotin-rituximab without a chemotherapy backbone demonstrated encouraging overall response rates up to 40%, highlighting both an appropriate alternative for patients unsuitable for chemotherapy and a new treatment option for bridging before leukapheresis in patients intended for CAR T-cell therapy. Furthermore, 7 of 12 patients with previous failure of CAR T-cell therapy responded to a pola-containing regimen. These findings suggest that pola may serve as effective salvage and bridging treatment of r/r LBCL patients.
Background: Idiopathic pulmonary fibrosis (IPF) is a disease with high 5-year mortality and few therapeutic options. Prostaglandin (PG) E2 exhibits antifibrotic properties and is reduced in bronchoalveolar lavage from patients with IPF. 15-Prostaglandin dehydrogenase (15-PGDH) is the key enzyme in PGE2 metabolism under the control of TGF-β and microRNA 218.
Objective: We sought to investigate the expression of 15-PGDH in IPF and the therapeutic potential of a specific inhibitor of this enzyme in a mouse model and human tissue.
Methods: In vitro studies, including fibrocyte differentiation, regulation of 15-PGDH, RT-PCR, and Western blot, were performed using peripheral blood from healthy donors and patients with IPF and A549 cells. Immunohistochemistry, immunofluorescence, 15-PGDH activity assays, and in situ hybridization as well as ex vivo IPF tissue culture experiments were done using healthy donor and IPF lungs. Therapeutic effects of 15-PGDH inhibition were studied in the bleomycin mouse model of pulmonary fibrosis.
Results: We demonstrate that 15-PGDH shows areas of increased expression in patients with IPF. Inhibition of this enzyme increases PGE2 levels and reduces collagen production in IPF precision cut lung slices and in the bleomycin model. Inhibitor-treated mice show amelioration of lung function, decreased alveolar epithelial cell apoptosis, and fibroblast proliferation. Pulmonary fibrocyte accumulation is also decreased by inhibitor treatment in mice, similar to PGE2 that inhibits fibrocyte differentiation from blood of healthy donors and patients with IPF. Finally, microRNA 218-5p, which is downregulated in patients with IPF, suppressed 15-PGDH expression in vivo and in vitro.
Conclusions: These findings highlight the role of 15-PGDH in IPF and suggest 15-PGDH inhibition as a promising therapeutic approach.
Objectives: The SAVI-TF (Symetis ACURATE neo Valve Implantation Using Transfemoral Access) registry was initiated to study the ACURATE neo transcatheter heart valve in a large patient population treated under real-world conditions.
Background: The self-expanding, supra-annular ACURATE neo prosthesis is a transcatheter heart valve that gained the Conformité Européene mark in 2014, but only limited clinical data are available so far.
Methods: This prospective, multicenter registry enrolled 1,000 patients at 25 European centers who were followed for 1 year post-procedure.
Results: Mean patient age was 81.1 ± 5.2 years; mean logistic European System for Cardiac Operative Risk Evaluation I score, European System for Cardiac Operative Risk Evaluation II score, and Society of Thoracic Surgeons score were 18.1 ± 12.5%, 6.6 ± 7.5%, and 6.0 ± 5.6%, respectively. At 1 year, 8.0% (95% confidence interval [CI]: 6.3% to 9.7%) of patients had died, 2.3% (95% CI: 1.3% to 3.2%) had disabling strokes, and 9.9% (95% CI: 8.1% to 11.8%) had permanent pacemaker implantations. Through 1 year, 5 reinterventions (0.5%; 95% CI: 0.1% to 1.0%) were performed: 3 valve-in-valve and 2 surgical aortic valve replacements. Mean effective orifice area was 1.84 ± 0.43 cm2, mean gradient was 7.3 ± 3.7 mm Hg, and greater than mild paravalvular leakage was observed in 3.6% of patients.
Conclusions: Transfemoral implantation of the ACURATE neo prosthesis resulted in favorable 1-year clinical and echocardiographic outcomes with very low mortality and new pacemaker rates.
New experimental data for dissociation of relativistic 17Ne projectiles incident on targets of lead, carbon, and polyethylene targets at GSI are presented. Special attention is paid to the excitation and decay of narrow resonant states in 17Ne. Distributions of internal energy in the three-body system have been determined together with angular and partial-energy correlations between the decay products in different energy regions. The analysis was done using existing experimental data on 17Ne and its mirror nucleus 17N. The isobaric multiplet mass equation is used for assignment of observed resonances and their spins and parities. A combination of data from the heavy and light targets yielded cross sections and transition probabilities for the Coulomb excitations of the narrow resonant states. The resulting transition probabilities provide information relevant for a better understanding of the 17Ne structure.
Bipolar disorder (BD) is a highly heritable neuropsychiatric disease characterized by recurrent episodes of mania and depression. BD shows substantial clinical and genetic overlap with other psychiatric disorders, in particular schizophrenia (SCZ). The genes underlying this etiological overlap remain largely unknown. A recent SCZ genome wide association study (GWAS) by the Psychiatric Genomics Consortium identified 128 independent genome-wide significant single nucleotide polymorphisms (SNPs). The present study investigated whether these SCZ-associated SNPs also contribute to BD development through the performance of association testing in a large BD GWAS dataset (9747 patients, 14278 controls). After re-imputation and correction for sample overlap, 22 of 107 investigated SCZ SNPs showed nominal association with BD. The number of shared SCZ-BD SNPs was significantly higher than expected (p = 1.46x10-8). This provides further evidence that SCZ-associated loci contribute to the development of BD. Two SNPs remained significant after Bonferroni correction. The most strongly associated SNP was located near TRANK1, which is a reported genome-wide significant risk gene for BD. Pathway analyses for all shared SCZ-BD SNPs revealed 25 nominally enriched gene-sets, which showed partial overlap in terms of the underlying genes. The enriched gene-sets included calcium- and glutamate signaling, neuropathic pain signaling in dorsal horn neurons, and calmodulin binding. The present data provide further insights into shared risk loci and disease-associated pathways for BD and SCZ. This may suggest new research directions for the treatment and prevention of these two major psychiatric disorders.
Background: To evaluate optimal therapy and potential risk factors.
Methods: Data of DSRCT patients <40 years treated in prospective CWS trials 1997‐2015 were analyzed.
Results: Median age of 60 patients was 14.5 years. Male:female ratio was 4:1. Tumors were abdominal/retroperitoneal in 56/60 (93%). 6/60 (10%) presented with a localized mass, 16/60 (27%) regionally disseminated nodes, and 38/60 (63%) with extraperitoneal metastases. At diagnosis, 23/60 (38%) patients had effusions, 4/60 (7%) a thrombosis, and 37/54 (69%) elevated CRP. 40/60 (67%) patients underwent tumor resection, 21/60 (35%) macroscopically complete. 37/60 (62%) received chemotherapy according to CEVAIE (ifosfamide, vincristine, actinomycin D, carboplatin, epirubicin, etoposide), 15/60 (25%) VAIA (ifosfamide, vincristine, adriamycin, actinomycin D) and, 5/60 (8%) P6 (cyclophosphamide, doxorubicin, vincristine, ifosfamide, etoposide). Nine received high‐dose chemotherapy, 6 received regional hyperthermia, and 20 received radiotherapy. Among 25 patients achieving complete remission, 18 (72%) received metronomic therapies. Three‐year event‐free (EFS) and overall survival (OS) were 11% (±8 confidence interval [CI] 95%) and 30% (±12 CI 95%), respectively, for all patients and 26.7% (±18.0 CI 95%) and 56.9% (±20.4 CI 95%) for 25 patients achieving remission. Extra‐abdominal site, localized disease, no effusion or ascites only, absence of thrombosis, normal CRP, complete tumor resection, and chemotherapy with VAIA correlated with EFS in univariate analysis. In multivariate analysis, significant factors were no thrombosis and chemotherapy with VAIA. In patients achieving complete remission, metronomic therapy with cyclophosphamide/vinblastine correlated with prolonged time to relapse.
Conclusion: Pleural effusions, venous thrombosis, and CRP elevation were identified as potential risk factors. The VAIA scheme showed best outcome. Maintenance therapy should be investigated further.
Increased sympathetic noradrenergic signaling is crucially involved in fear and anxiety as defensive states. MicroRNAs regulate dynamic gene expression during synaptic plasticity and genetic variation of microRNAs modulating noradrenaline transporter gene (SLC6A2) expression may thus lead to altered central and peripheral processing of fear and anxiety. In silico prediction of microRNA regulation of SLC6A2 was confirmed by luciferase reporter assays and identified hsa-miR-579-3p as a regulating microRNA. The minor (T)-allele of rs2910931 (MAFcases = 0.431, MAFcontrols = 0.368) upstream of MIR579 was associated with panic disorder in patients (pallelic = 0.004, ncases = 506, ncontrols = 506) and with higher trait anxiety in healthy individuals (pASI = 0.029, pACQ = 0.047, n = 3112). Compared to the major (A)-allele, increased promoter activity was observed in luciferase reporter assays in vitro suggesting more effective MIR579 expression and SLC6A2 repression in vivo (p = 0.041). Healthy individuals carrying at least one (T)-allele showed a brain activation pattern suggesting increased defensive responding and sympathetic noradrenergic activation in midbrain and limbic areas during the extinction of conditioned fear. Panic disorder patients carrying two (T)-alleles showed elevated heart rates in an anxiety-provoking behavioral avoidance test (F(2, 270) = 5.47, p = 0.005). Fine-tuning of noradrenaline homeostasis by a MIR579 genetic variation modulated central and peripheral sympathetic noradrenergic activation during fear processing and anxiety. This study opens new perspectives on the role of microRNAs in the etiopathogenesis of anxiety disorders, particularly their cardiovascular symptoms and comorbidities.
Objectives: The aim of this multicenter retrospective study was to investigate safety and efficacy of direct acting antiviral (DAA) treatment in the rare subgroup of patients with HCV/HIV-coinfection and advanced liver cirrhosis on the liver transplant waiting list or after liver transplantation, respectively.
Methods: When contacting 54 German liver centers (including all 23 German liver transplant centers), 12 HCV/HIV-coinfected patients on antiretroviral combination therapy were reported having received additional DAA therapy while being on the waiting list for liver transplantation (patient characteristics: Child-Pugh A (n = 6), B (n = 5), C (n = 1); MELD range 7–21; HCC (n = 2); HCV genotype 1a (n = 8), 1b (n = 2), 4 (n = 2)). Furthermore, 2 HCV/HIV-coinfected patients were denoted having received DAA therapy after liver transplantation (characteristics: HCV genotype 1a (n = 1), 4 (n = 1)).
Results: Applied DAA regimens were SOF/DAC (n = 7), SOF/LDV/RBV (n = 3), SOF/RBV (n = 3), PTV/r/OBV/DSV (n = 1), or PTV/r/OBV/DSV/RBV (n = 1), respectively. All patients achieved SVR 12, in the end. In one patient, HCV relapse occurred after 24 weeks of SOF/DAC therapy; subsequent treatment with 12 weeks PTV/r/OBV/DSV achieved SVR 12. One patient underwent liver transplantation while on DAA treatment. Analysis of liver function revealed either stable parameters or even significant improvement during DAA therapy and in follow-up. MELD scores were found to improve in 9/13 therapies in patients on the waiting list for liver transplantation; in only 2 patients a moderate increase of MELD scores persisted at the end of follow-up.
Conclusion: DAA treatment was safe and highly effective in this nation-wide cohort of patients with HCV/HIV-coinfection awaiting liver transplantation or being transplanted.
Background and Aims. Systemic treatment with sorafenib has been the standard of care (SOC) in patients with advanced Barcelona Clinic Liver Cancer (BCLC) stage C hepatocellular carcinoma (HCC) for more than a decade. TACE has been reported to allow better local tumor control in selected patients with BCLC stage C HCC. Methods. A retrospective analysis of patients with BCLC stage C HCC that were treated with sorafenib and TACE was conducted; they were compared to BCLC stage C patients treated either with TACE or sorafenib in the same period of time outside a clinical trial. Results. A total of 201 patients with BCLC stage C were identified, who were treated with either sorafenib and TACE (group A; n = 54), sorafenib (group B; n = 82) or TACE (group C; n = 65). No significant difference in baseline characteristics was observed. Time to progression was 7.0 months (95% CI: 4.3–9.7), 4.1 months (95% CI: 3.6–4.7) and 5.0 months (95% CI: 2.9–7.1) in groups A, B and C, respectively, and overall survival was 16.5 months (95% CI: 15.0–18.1), 8.4 months (95% CI: 6.0–10.8) and 10.5 months (95% CI: 7.5–13.6), respectively (group A vs. group B: p < 0.001; group A vs. group C: p = 0.0023). Adverse events of grade 3/4 occurred in 34% of patients in group A. Conclusions. Although sorafenib is a SOC in patients with BCLC stage C HCC, TACE is frequently used as an additional locoregional treatment in selected patients. This combined approach resulted in a significant overall survival benefit in selected patients, although randomized trials have not yet proven this benefit.
As one of the first Direct Acting Antivirals (DAA), the protease inhibitor Telaprevir (TVR) was available in the European Union from 9/2011 until 9/2016 as a new treatment option for chronic Hepatitis C.Aim. To assess the implementation of therapy stopping rules or shortening of the treatment and their impact on sustained virological response (SVR), as well as the safety and efficacy of the TVR-based therapy during routine daily treatment of patients in Germany.Materials and Methods. 802 patients were assessed (272 treatment naïve, 520 pre-treated) in the noninterventional, multi-center study.Results. 56.6 % of the patients achieved SVR. SVR rate was higher in patients with relapse after previous treatment (68.0 %) than in patients with a previous null-response (31.1 %) and in previously untreated patients (58.1 %). Stopping rule conditions were fulfilled by 3.2 % of patients and it was implemented in 65.4 % of these. 34.3 % of the patients fulfilled the conditions for a therapy shortening. This rule was adhered to in 48.4 % of these, in 34.5 % it was not adhered to. Thus recommendations were not always being followed. Therapy shortening was considered more frequently in previously untreated (54.8 %) than for previously treated patients (24.2 %). Stopping rule application but not shortened treatment reduced therapy costs.Conclusion. The TVR-based therapy represented a breakthrough at that time. Further DAAs have been added as therapeutic options since, increasing the complexity of treatment choice and correct implementation. They represent both an opportunity and a challenge for all those involved.As one of the first Direct Acting Antivirals (DAA), the protease inhibitor Telaprevir (TVR) was available in the European Union from 9/2011 until 9/2016 as a new treatment option for chronic Hepatitis C.Aim. To assess the implementation of therapy stopping rules or shortening of the treatment and their impact on sustained virological response (SVR), as well as the safety and efficacy of the TVR-based therapy during routine daily treatment of patients in Germany.Materials and Methods. 802 patients were assessed (272 treatment naïve, 520 pre-treated) in the noninterventional, multi-center study.Results. 56.6 % of the patients achieved SVR. SVR rate was higher in patients with relapse after previous treatment (68.0 %) than in patients with a previous null-response (31.1 %) and in previously untreated patients (58.1 %). Stopping rule conditions were fulfilled by 3.2 % of patients and it was implemented in 65.4 % of these. 34.3 % of the patients fulfilled the conditions for a therapy shortening. This rule was adhered to in 48.4 % of these, in 34.5 % it was not adhered to. Thus recommendations were not always being followed. Therapy shortening was considered more frequently in previously untreated (54.8 %) than for previously treated patients (24.2 %). Stopping rule application but not shortened treatment reduced therapy costs.Conclusion. The TVR-based therapy represented a breakthrough at that time. Further DAAs have been added as therapeutic options since, increasing the complexity of treatment choice and correct implementation. They represent both an opportunity and a challenge for all those involved.
Background and aims: Patients with gastric cancer often show signs of malnutrition. We sought to evaluate the influence of sarcopenia in patients with locally advanced, not metastasized, gastric or gastro-esophageal junction (GEJ) cancer undergoing curative treatment (perioperative chemotherapy and surgery) on morbidity and mortality in order to identify patients in need for nutritional intervention.
Patients and methods: Two-centre study, conducted in the Frankfurt University Clinic and Krankenhaus Nordwest (Frankfurt) as part of the University Cancer Center Frankfurt (UCT). 47/83 patients were treated in the FLOT trial (NCT01216644). Patients´ charts were reviewed for clinical data. Two consecutive CT scans were retrospectively analyzed to determine the degree of sarcopenia. Survival was calculated using the Kaplan-Meier method, multivariate analysis was performed using the Cox regression.
Results: 60 patients (72.3%) were male and 23 (27.7%) female. 45 patients (54.2%) had GEJ type 1–3 and 38 (45.8%) gastric tumors, respectively. Sarcopenic patients were significantly older than non-sarcopenic patients (mean age 65.1 years vs. 59.5 years, p = 0.042), terminated the chemotherapy significantly earlier (50% vs. 22.6%, p = 0.037) and showed higher Clavien-Dindo scores, indicating more severe perioperative complications (score ≥3 43.3 vs. 17.0%, p = 0.019). Sarcopenic patients had a significantly shorter survival than non-sarcopenic patients (139.6 ± 19.5 [95% CI, 101.3–177.9] vs. 206.7 ± 13.8 [95% CI, 179.5–233.8] weeks, p = 0.004). Multivariate Cox regression analysis showed that, besides UICC stage, sarcopenia significantly influenced survival.
Conclusion: Sarcopenia is present in a large proportion of patients with locally advanced gastric or GEJ cancer and significantly influences tolerability of chemotherapy, surgical complications and survival.
In psychiatry, there has been a growing focus on identifying at-risk populations. For schizophrenia, these efforts have led to the development of early recognition and intervention measures. Despite a similar disease burden, the populations at risk of bipolar disorder have not been sufficiently characterized. Within the BipoLife consortium, we used magnetic resonance imaging (MRI) data from a multicenter study to assess structural gray matter alterations in N = 263 help-seeking individuals from seven study sites. We defined the risk using the EPIbipolar assessment tool as no-risk, low-risk, and high-risk and used a region-of-interest approach (ROI) based on the results of two large-scale multicenter studies of bipolar disorder by the ENIGMA working group. We detected significant differences in the thickness of the left pars opercularis (Cohen’s d = 0.47, p = 0.024) between groups. The cortex was significantly thinner in high-risk individuals compared to those in the no-risk group (p = 0.011). We detected no differences in the hippocampal volume. Exploratory analyses revealed no significant differences in other cortical or subcortical regions. The thinner cortex in help-seeking individuals at risk of bipolar disorder is in line with previous findings in patients with the established disorder and corresponds to the region of the highest effect size in the ENIGMA study of cortical alterations. Structural alterations in prefrontal cortex might be a trait marker of bipolar risk. This is the largest structural MRI study of help-seeking individuals at increased risk of bipolar disorder.
Objective: Liver stiffness measurement (LSM) is a tool used to screen for significant fibrosis and portal hypertension. The aim of this retrospective multicentre study was to develop an easy tool using LSM for clinical outcomes in advanced chronic liver disease (ACLD) patients.
Design: This international multicentre cohort study included a derivation ACLD patient cohort with valid two-dimensional shear wave elastography (2D-SWE) results. Clinical and laboratory parameters at baseline and during follow-up were recorded. LSM by transient elastography (TE) was also recorded if available. The primary outcome was overall mortality. The secondary outcome was the development of first/further decompensation.
Results: After screening 2148 patients (16 centres), 1827 patients (55 years, 62.4% men) were included in the 2D-SWE cohort, with median liver SWE (L-SWE) 11.8 kPa and a model for end stage liver disease (MELD) score of 8. Combination of MELD score and L-SWE predict independently of mortality (AUC 0.8). L-SWE cut-off at ≥20 kPa combined with MELD ≥10 could stratify the risk of mortality and first/further decompensation in ACLD patients. The 2-year mortality and decompensation rates were 36.9% and 61.8%, respectively, in the 305 (18.3%) high-risk patients (with L-SWE ≥20 kPa and MELD ≥10), while in the 944 (56.6%) low-risk patients, these were 1.1% and 3.5%, respectively. Importantly, this M10LS20 algorithm was validated by TE-based LSM and in an additional cohort of 119 patients with valid point shear SWE-LSM.
Conclusion: The M10LS20 algorithm allows risk stratification of patients with ACLD. Patients with L-SWE ≥20 kPa and MELD ≥10 should be followed closely and receive intensified care, while patients with low risk may be managed at longer intervals.
Molecular surveillance of carbapenem-resistant gram-negative bacteria in liver transplant candidates
(2021)
Background: Carbapenem-resistant Gram-negative bacteria (CRGN) cause life-threatening infections due to limited antimicrobial treatment options. The occurrence of CRGN is often linked to hospitalization and antimicrobial treatment but remains incompletely understood. CRGN are common in patients with severe illness (e.g., liver transplantation patients). Using whole-genome sequencing (WGS), we aimed to elucidate the evolution of CRGN in this vulnerable cohort and to reconstruct potential transmission routes.
Methods: From 351 patients evaluated for liver transplantation, 18 CRGN isolates (from 17 patients) were analyzed. Using WGS and bioinformatic analysis, genotypes and phylogenetic relationships were explored. Potential epidemiological links were assessed by analysis of patient charts.
Results: Carbapenem-resistant (CR) Klebsiella pneumoniae (n=9) and CR Pseudomonas aeruginosa (n=7) were the predominating pathogens. In silico analysis revealed that 14/18 CRGN did not harbor carbapenemase-coding genes, whereas in 4/18 CRGN, carbapenemases (VIM-1, VIM-2, OXA-232, and OXA-72) were detected. Among all isolates, there was no evidence of plasmid transfer-mediated carbapenem resistance. A close phylogenetic relatedness was found for three K. pneumoniae isolates. Although no epidemiological context was comprehensible for the CRGN isolates, evidence was found that the isolates resulted of a transmission of a carbapenem-susceptible ancestor before individual radiation into CRGN.
Conclusion: The integrative epidemiological study reveals a high diversity of CRGN in liver cirrhosis patients. Mutation of carbapenem-susceptible ancestors appears to be the dominant way of CR acquisition rather than in-hospital transmission of CRGN or carbapenemase-encoding genetic elements. This study underlines the need to avoid transmission of carbapenem-susceptible ancestors in vulnerable patient cohorts.
Neurowissenschaftler fordern einen illusionslosen Umgang mit Begriffen wie Willensfreiheit und Bewusstsein. Philosophen kritisieren offen die Thesen von Hirnforschern. Stehen sich diese Positionen unversöhnlich gegenüber? Wo gibt es Möglichkeiten einer Annäherung, gar einer Kooperation? Der Religionsphilosoph Prof. Dr. Thomas M. Schmidt und der Biologe Stefan Kieß loten die Situation in Frankfurt aus; ihre Gesprächspartner sind der Hirnforscher Prof. Dr. Wolf Singer (links), Direktor am Max-Planck-Institut für Hirnforschung, und Prof. Dr. Marcus Willaschek (rechts), Philosoph an der Universität Frankfurt.
New results from the energy scan programme of NA49, in particular kaon production at 30 AGeV and phi production at 40 and 80 AGeV are presented. The K+/pi+ ratio shows a pronounced maximum at 30 AGeV; the kaon slope parameters are constant at SPS energies. Both findings support the scenario of a phase transition at about 30 AGeV beam energy. The phi/pi ratio increases smoothly with beam energy, showing an energy dependence similar to K-/pi-. The measured particle yields can be reproduced by a hadron gas model, with chemical freeze-out parameters on a smooth curve in the T-muB plane. The transverse spectra can be understood as resulting from a rapidly expanding, locally equilibrated source. No evidence for an earlier kinetic decoupling of heavy hyperons is found.
Directed and elliptic flow of charged pions and protons in Pb + Pb collisions at 40 and 158 A GeV
(2003)
Directed and elliptic flow measurements for charged pions and protons are reported as a function of transverse momentum, rapidity, and centrality for 40 and 158A GeV Pb + Pb collisions as recorded by the NA49 detector. Both the standard method of correlating particles with an event plane, and the cumulant method of studying multiparticle correlations are used. In the standard method the directed flow is corrected for conservation of momentum. In the cumulant method elliptic flow is reconstructed from genuine 4, 6, and 8-particle correlations, showing the first unequivocal evidence for collective motion in A+A collisions at SPS energies.
Das Herbarium des Pfarrers Adolf Becker, gesammelt zwischen 1833 und 1863, wurde nachbestimmt. Bei der Mehrzahl der etwa 200 mit Fundorten versehenen Belege handelt es sich um Kulturpflanzen, die vornehmlich in Parkanlagen von Bad Homburg v. d. Höhe und Okarben gesammelt wurden. Diese geben einen Eindruck von den erstaunlich reichhaltigen Bepflanzungen jener Zeit. 81 von uns als Wildpflanzen klassifizierte Arten wurden zumeist um Okarben gesammelt. Wegen ihres Rückganges oder aktuellen Fehlens sind die Belege von Apium graveolens, A. nodiflorum, Juncus gerardii, Nigella arvensis und Oenanthe fistulosa bemerkenswert.